Ongoing trials such as DESTINY-Gastric03 (trastuzumab deruxtecan in HER2-positive GC) and SKYSCRAPER-07 (tiragolumab + atezolizumab in ESCC) will provide further insights as to the roles of targeted agents and immunotherapy (91, 92). This evidence concerns the gene ERBB2 and gastric cancer.